Aurealis Therapeutics

Recent Finacing

Series A

Recent Raise

$10M

Aurealis Therapeutics develops engineered food-grade lactic acid bacteria as in vivo nanoscale bioreactors to deliver multivalent therapeutic proteins, advancing AUP-16 for chronic wounds through clinical trials and AUP-55 preclinically.

Founded 2015

Eastern Finland, Finland

11-50

Private

aurealistherapeutics.com

Highlights

Focus Areas

Biotechnology

Pharmaceutical

Therapeutics

Recent Investors

L

Financials

$10M

Total Raised

1

Funding round

3

Investors

Team

Upgrade to view the team

See the team members at Aurealis Therapeutics.